Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
ASCO
American Society of Clinical Oncology, Gastrointestinal (ASCO-GI)
January 23, 2023
,
El-Khoueiry, et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
A Phase IA/IB study of Botensilimab, a novel innate/adaptive immune activator, plus Balstilimab for the treatment of patients with sarcoma
CTOS
Connective Tissue Oncology Society (CTOS)
November 18, 2022
,
Wilky, et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab, a novel innate/adaptive immune activator with balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
SITC
Society for Immunotherapy of Cancer (SITC)
November 14, 2022
,
Wilky, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab, a novel Fc-enhanced anti-CTLA-4 antibody enhances T cell: APC functionality and promotes superior anti-tumor immunity
SITC
Society for Immunotherapy of Cancer (SITC)
November 14, 2022
,
Levey, et al.
No items found.